Restylane®Lidocain and Perlane®Lidocain approved in USA
(Thomson Reuters ONE) - Restylane®Lidocain and Perlane®Lidocain has been approved by FDA(U.S. Food and Drug Administration). The products will now be available on theUS market by Q-Meds partner Medicis. Lidocain is a local anaesthetic.In clinicalstudies supporting approval, the addition of lidocaine to Restylane and Perlanesubstantially reduced pain experienced by patients.Please read the full press release from Medicis:http://www.irconnect.com/mrx/pages/news_releases.html?d=183418Queries should be addressed to:Alexander Kotsinas, Vice President and CFOTel: +46 (0)73-500 1111Bengt ?erup, President and CEOTel: +46 (0)70-974 9025Q-Med AB is a medical device company. The company develops, manufactures,markets, and sells primarily medical implants. The majority of the products arebased on the company's patented technology, NASHA(TM), for the production ofstabilized non-animal hyaluronic acid. The product portfolio today contains:Restylane® for filling lines and folds, contouring and creating volume in theface, Macrolane(TM) for body contouring, Durolane(TM) for the treatment ofosteoarthritis of the hip and knee joints, Deflux® for the treatment ofvesicoureteral reflux, VUR,(a malformation of the urinary bladder) in children, andSolesta(TM) for thetreatment of fecal incontinence. Sales are made through the company's ownsubsidiaries or distributors in over 70 countries. Q?Med today has about 650coworkers, with approximately 400 at the company's head office and productionfacility in Uppsala, Sweden.Q-Med AB is listed in the Mid Cap segment of theNASDAQ OMX Nordic.Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden.Corporate identity number 556258-6882. Tel: +46 18 474 90 00. Fax: +46 18 474 90 01.E-mail: info(at)q-med.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2010 - 11:29 Uhr
Sprache: Deutsch
News-ID 1009957
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Uppsala
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 119 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Restylane®Lidocain and Perlane®Lidocain approved in USA
"
steht unter der journalistisch-redaktionellen Verantwortung von
Q-Med AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
